Brivaracetam
- Generic Name
- Brivaracetam
- Brand Names
- Briviact, Briviact (in Italy: Nubriveo)
- Drug Type
- Small Molecule
- Chemical Formula
- C11H20N2O2
- CAS Number
- 357336-20-0
- Unique Ingredient Identifier
- U863JGG2IA
- Background
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
- Indication
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT00175825
A Study of Brivaracetam in Subjects With Partial Onset Seizures
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 157
- Registration Number
- NCT00175929
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 152
- Registration Number
- NCT00160667
This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB PHARMA Inc. (US)
- Target Recruit Count
- 668
- Registration Number
- NCT00150800
- Locations
- 🇺🇸
N01199 1392, Newport Beach, California, United States
🇺🇸N01199 1396, Atlanta, Georgia, United States
🇺🇸N01199 1077, Burlington, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath